|
Is Chemo & Radiation The Best Option?

Electron micrograph of a single breast cancer cell.
The most controversial issue in health-care today. We are determined to provide you with the most scientific research there is regarding cancer treatment effectiveness & safety. While we are not qualified to diagnose or treat cancer we will bring you the latest research regarding cancer treatments so you can make the decision that is right for you. What you are about to read can alter the course of your life from here forward. We recommend you share this page with as many people as you can. Much of the research here is done by Oncologists, Physicians and Scientists.
Cancer is considered a death sentence by many. Yet how much do we really know about cancer? What lies below will detail the therapies used today and why we feel they need to cease the treatments and begin practicing other modalities that are proven far more effective & safe!
If the concerns outweigh the benefits than we ought to rethink our position.
Cancer is considered a death sentence by many. Yet how much do we really know about cancer? What lies below will detail the therapies used today and why we feel they need to cease the treatments and begin practicing other modalities that are proven far more effective & safe!
If the concerns outweigh the benefits than we ought to rethink our position.
NEW potential treatment for brain and lung cancer
Tumor treating fields therapy (TTF) which uses electrical current directed at cancer cells in the brain or lung to disrupt the cancer cell growth. Promising clinical trials are under phase 3 in testing. This is a very promising treatment. Here is the company and clinical trial information. Novocure sponsored research. Here is the list of clinical trial information.
Here is a great video presentation of cancer cells having a very difficult time dividing due to the TTF treatment.
Tumor treating fields therapy (TTF) which uses electrical current directed at cancer cells in the brain or lung to disrupt the cancer cell growth. Promising clinical trials are under phase 3 in testing. This is a very promising treatment. Here is the company and clinical trial information. Novocure sponsored research. Here is the list of clinical trial information.
Here is a great video presentation of cancer cells having a very difficult time dividing due to the TTF treatment.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
|
~ We've decided to collect funds to leverage more resources to grow this website, educational campaigns and material to inform the public of the health benefits of natural approaches to cancer even at advanced stages. Our goal is to reach a tipping point through scientific and ethical discussion regarding the cancer industry so that you may have the freedom to choose any therapy you wish without the persecution of government entities.
Hemp oil, Marijuana Therapy, Gerson Therapy, Burzynski's Therapy, Nutraceuticals, etc. It's your body and life. You have the right to know and choose healthier more effective models of treatment/prevention. ~ |
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
“The right thing to do never requires any subterfuge, it is always simple and direct.”
Calvin Coolidge
“The right thing to do never requires any subterfuge, it is always simple and direct.”
Calvin Coolidge
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
We don't disagree that chemo or radiation kills cancer. What we want others to be aware of is it often kills you too.
We are here to shine light on the science behind all of it. Integrative, alternative and even fringe therapies.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
We don't disagree that chemo or radiation kills cancer. What we want others to be aware of is it often kills you too.
We are here to shine light on the science behind all of it. Integrative, alternative and even fringe therapies.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
A study on 5-year survival in adult malignancies via cytotoxic chemotherapy. Journal of Clinical Oncology (2004)
Results: The overall contributions of curative and adjuvant cytotoxic chemotherapy in 5-year survival was estimated to be 2.3% in Australia and 2.1% in the USA.
Morgan, G. et al. (2004). Clinical Oncology 16, 549e560
Is a mere 2.3% or 2.1% a good enough result to continue chemotherapy?
Results: The overall contributions of curative and adjuvant cytotoxic chemotherapy in 5-year survival was estimated to be 2.3% in Australia and 2.1% in the USA.
Morgan, G. et al. (2004). Clinical Oncology 16, 549e560
Is a mere 2.3% or 2.1% a good enough result to continue chemotherapy?
![]()
|
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Got Cancer?
Clinics/Doctors currently treating cancer today:
(Alphabetically organized, research all of these clinics/practitioners/info)
- Burzynski Clinic (Antineoplaston therapy. Unfortunately by law it may be required to do chemo 1st which makes this therapy far less effective.)
- Center For New Medicine (Works in conjunction with Oasis of Hope Hospital)
- Dr. Gonzalez Individualized Nutritional Protocols (Enzyme therapy. Alternative therapy, sophisticated blood testing.)
- Gerson Institute Clinics (Alternative therapies, raw juicing, coffee enemas, extensive Japanese Medical Doctors doing research on this now.)
- Oasis of Hope Hospital (Statistics in comparison to conventional treatment alone. Integrative clinic some chemo used in specific cases.)
Doctors/Practitioners:
Dr. Leigh Erin Connealy, M.D., M.P.H.
Keynotes of Dr. Leigh's Approach (NOT a complete list): Seek consultation before following recommendations this is for educational puposes only
- Avoid ALL fruits/sugar, lemons, limes & avocados are the only fruits she recommends you eat if you have cancer due to sugar content
- Eliminate soy due to estrogenic effect and GMO likelihood which could upregulate certain cancers
- Avoid all carbonated beverages (it takes 10 gallons of water to nutralize the acid of 1 can of soda)
- A minimum absoulte requirement of coffee enemas done 5 times a week at minimum
- Colon cleansin/parasite flushing in conjunction with therapies
- 5,000 - 10,000 international units of vitamin D3 a day
- Fish oil or chia seeds for healthy fatty acid profile
- Daily detox using oral zeolite
- Infra-red sauna detoxification
- Body brushing
- We all have 750,000 cancer cells within our body, cancer cells have 96 receptor sites & healthy cell has 4 receptor sites
- Pancreatic Enzymes (such enzymes etch off the fibrin coating that all cancers use to protect themselves, there are precisely 17 layers of fibrin in every tumor and these enzymes break-down the fibrin in order for your immune system/nutraceuticals to address the cancer proliferation)
- Effective nutraceuticals for cancer from her clinical findings are: milk thistle, green tea, resveratrol, turmeric, vitamin C {due to it increasing endogenous hydrogen peroxide}, boswalic acid, modified citrus pectin {prevents metastasis of breast & prostate cancer}, shark oil {Antiangiogenesis: inhibits growth of new blood vessels to tumors as shown in studies}
Dr. Francisco Contreras, M.D. (Integrated Regulatory Therapy Hospital in Mexico)
Keynotes of Dr. Francisco's Approach (NOT a complete list): Seek consultation before following recommendations this is for educational puposes only
- Reduce consumption of high-quality protein (red meat), simple sugars and fatty foods IF you have cancer
- Management of inflammation with enzyme therapy (digestive, pancreatic) and improve digestion of foods
- Alkaline-rich foods such as green juices/powders with very low sugar content (wheat grass, spirulina, chlorella, etc.)
- Avoid ALL fruits/sugar, lemons, limes & avocados are the only fruits recommended you eat if you have cancer due to sugar content
- A Vegan diet is recommended for cancer patients based off their clinical findings with NO processed foods and while sugar feeds cancer it has been found that cancer cannot take advantage of complex carbohydrates as found in certain fruits and vegetables
- Control the two most important elements to cancer growth via nutritional and lifestyle therapies which are: insulin-like growth factor and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells)
- X-Rays & laboratory tests for tumor markers used to track the progress of cancer therapies and present accurate statistics which is very similar the MD Anderson approach
- Laetrile therapy releases small levels of cyanide that cause damage to cancerous cells (not really vitamin B17 as typically misunderstood coming from apricot seeds, having been in use since 1960) better for slow-growing cancers not fast-growing cancers, consume bitter almonds as part of cancer therapy
- Pancreatic Enzymes (such enzymes etch off the fibrin
coating that all cancers use to protect themselves, there are precisely
17 layers of fibrin in every tumor and these enzymes break-down the
fibrin in order for your immune system/nutraceuticals to address the
cancer proliferation)
- Effective nutraceuticals for cancer from her clinical findings are: grape-seed extract, green tea, resveratrol, turmeric, vitamin C {due to it increasing endogenous hydrogen peroxide}, modified citrus pectin {prevents metastasis of breast & prostate cancer}, shark oil {Antiangiogenesis: inhibits growth of new blood vessels to tumors as shown in studies}
- Significant doses of vitamin C intravenous therapies which converts it from an antioxidant to an powerful oxidant to increase oxidative stress on the cancer attacking cancers oxidative stress potential for they have poor protection against oxidative stress (this is how chemo and radiation works essentially however at the costs of healthy cells) Most tumors are hypoxic (reduced oxygen levels), increase the amount of oxygen in the tumor while giving the body systemic antioxidant protection for healthy cells
- Extensive statistics of a comparison between conventional therapy results and his integrative therapy results for Breast, Colorectol, Lung & Ovarian Cancer Survival Rates. Using terminal 4 stage cancers. At the end of 5 years almost 3 times higher the survival rate than conventional therapy along with a significantly improved quality of life for the above cancers
- We must change our philosophy from fighting the tumor to providing the body and patient with the correct environment to heal. First Do No Harm! Using conventional and integrative therapies that have been shown effective in the treatment of cancer. Emotional & spiritual needs must be addressed.
- Restrained & detrimental emotions have a big effect on cancer growth for it directly effects your immune system (chemical composition of your tears is different if you cry tears of sorrow or tears of happiness). Hopelessness is one of the biggest issues facing clients with cancer. Additionally the most immune-supportive color currently found is mauve [pale lavender-lilac color] the most immune-supressive colors currently found are white and blue.
- Approximately 1% of stage 4 lung cancer patients die within
1st year using conventional therapy. Approximately 19% of stage 4 lung
cancer patients survive after 5 years using Integrative Regulatory
Therapy (Oasis of Hope Therapies)
- Terminal breast cancer patients (after having received chemo) 98% of their patients are alive after 5 years only 65% are alive for conventional treatments. If terminal breast cancer patients had no chemo 100% of them are alive after 1 year. Stage 4 cancer patients at the end of 5 years that suffer virtually no side-effects there is a survival rate 40-45% compared to 15-20% via conventional therapies
- Genetics have very very little to do with cancer, there is only one proven genetic cancer which is known as familial adenomatous polyposis. For example there are breast cancer genes called BRCA1 and BRCA2 a study was done showing that while you may have genes they absolutely have to be upregulated via diet, lifestyle and toxicity exposure whether or not you have these genes matters very little if you follow a healthy lifestyle (which downregulates genetic expression)
Dr. Alexander Herzog, M.D. (psychological and emotional aspects of cancer)
Dr. Nicholas Gonzalez, M.D.
Dr. Max Gerson, M.D.
Dr. Stanislaw Burzynski, M.D. (Creator of Antineoplaston therapy)
Dr. Tullio Simoncini, M.D. (Italian Oncologist who advocates sodium bicarbonate therapy, cancer is a fungus theory)
Dr. William Donald Kelley, D.D.S., M.S. (Out of 33,000 clients a cure-rate of over 92% are claimed)
Burton Goldberg (cancer consultant (415) 725-3555)
Documentaries:
- Burzynski (Cancer therapy)
- Cancer is Curable Now (Investigation with leaders in integrative/alternative therapies for curing cancer)
- Cancer: The Forbidden Cures (Investigation into historic holistic cancer cures from Gerson to earlier days)
- Clearing The Smoke: The Science of Cannabis (Marijuana, Cancer Therapies)
- Cut, Poison, Burn (Cancer industry) *trailer*
- Dying To Have Known (Cancer Therapy, Gerson Therapy . .WOW)
- Run From The Cure (Cancer, Marijuana, Hemp)
- The Gerson Miracle (Cancer therapy)
Must-Read E-Books:
- Online Cancer book Victory Over Cancer
- Online Free E-Book for Spirulina & Chlorella Algae (not just Cancer, incredible information)
Must-Read Articles:
- The cure for wasted cancer fund donations
- FDA finally admits chicken meat contains cancer-causing arsenic (but keep eating it, yo!)
- Startling findings - ovarian cancer screening doesn't save lives and not all ovarian cancers kill or need treatment
- Miracle herbal supplement proven to aid victims of cancer treatments
- The FDA assaults breast thermography while protecting mammography industry
- Do cell phones cause cancer?
- Magnesium Offers Strong Radiation Protection
- Traditional Indian plant medicine may halt breast cancer metastasis
- Maybe you aren't doomed to cancer or other diseases because of your genes; scientists find risk research is inaccurate
- Mushroom compound heals cancer stem cells and prevents tumors
- Red meat and processed meat raise colon cancer risk, while fiber lowers it
- Scientists reverse stance on sun and cancer: Now they admit sunlight can prevent skin cancer
- Breast cancer breakthrough - Parsley and other plant products halt tumor growth
- Chemotherapy Statistics Can Be Misleading
- Cancer's Sweet Tooth
- Winning The War On Cancer
- Two words you should never utter to your doctor
- Can selenium protect you from cancer?
- New Discovery Shakes the Foundation of Cancer Research
Must-See Videos:
- MSNBC: Rewriting legalization of marijuana (YOU HAVE TO WATCH THIS! It's under 4 minutes.)
- Sodium Bicarbonate and Cancer Treatment - Mark Sircus, Ac., OMD
- Cancer Cured in Canada But Big Pharma Says 'NO WAY'!
- * CANCER CURE BANNED by Government to enrich drug companies!
- CANCER - The Forbidden Cures - TRAILER
- Suzanne Somers Throws Knockout for Cancer
- #2 Burzynski, The Movie - Trailer No. 2 - CANCER - DVD now available
- Burzynski Clinic, Houston's Premier Cancer Treatment Center
- An Illegal Cancer Cure = Genocide
- Clearing the Smoke: The Science of Cannabis Part 1
- Chemotherapy Is A Waste of Money
- Gregg Braden on Curing Cancer using our own Technology of Emotion (very interesting research near end of talk)
- Dr. Wade Adams: Nanotechnology & Energy (Brilliant Cancer Nano-Medicine early in the talk around 6 min marker)
Cancer Research
Cannabinoid, marijuana, hemp:
101. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells.
102. Effects on cell viability.
103. Cannabinoids and the digestive tract.
104. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells.
105. Cannabinoids in medicine: A review of their therapeutic potential.
106. [Cannabis and cancer].
107. New insights into endocannabinoid degradation and its therapeutic potential.
108. Cannabinoids and cancer: pros and cons of an antitumour strategy.
109. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism.
110. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells.
111. Anandamide inhibits adhesion and migration of breast cancer cells.
112. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma.
113. Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma.
114. R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells.
115. Cannabis and tobacco smoke are not equally carcinogenic.
116. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.
117. p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells.
118. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2.
119. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.
120. Cannabinoids and cancer: potential for colorectal cancer therapy.
121. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol . . .
122. [Palliative pain therapy, cannabinoids].
123. Cannabinoid receptor as a novel target for the treatment of prostate cancer.
124. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism.
125. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion.
126. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain.
127. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas.
128. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans.
129. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation.
130. Hypothesis: cannabinoid therapy for the treatment of gliomas?
131. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids.
132. [Cannabinoids and the immune system. Of men, mice and cells].
133. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1.
134. Cannabinoid receptor systems: therapeutic targets for tumour intervention.
135. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines.
136. Cannabinoids: potential anticancer agents.
137. The cannabinoid system and immune modulation.
138. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals . . .
139. Possible endocannabinoid control of colorectal cancer growth.
140. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor . . .
141. [The endocannabinoid system as a target for the development of new drugs for cancer therapy].
142. Pharmacokinetics and pharmacodynamics of cannabinoids.
143. Established and potential therapeutic applications of cannabinoids in oncology.
144. Inhibition of tumor angiogenesis by cannabinoids.
145. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.
146. Cannabinoids and cell fate.
147. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.
148. Endocannabinoids in the immune system and cancer.
149. Oxidative metabolism of endocannabinoids.
150. [Potential therapeutic usefulness of cannabis and cannabinoids].
(end on 207 of 809 cannabinoid cancer on 10/05/11)
(end on 249 of 809 cannabinoid cancer on 10/05/11)
(end on 356 of 809 cannabinoid cancer on 10/06/11)
(end on 410 of 809 cannabinoid cancer on 10/07/11)
(end on 532 of 809 cannabinoid cancer on 10/08/11)
Dr. Burzynski Antineoplaston Therapy:
Raw Juicing & Cancer:
Resveratrol:
101. Resveratrol inhibits proliferation and promotes apoptosis of neuroblastoma cells: role of sirtuin 1.
102. Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by inhibiting leukotriene A₄hydrolase.
103. Resveratrol enhances anti-proliferative effect of VACM-1/cul5 in T47D cancer cells.
104. Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular carcinoma Huh-7 cells.
105. Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies.
106. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin . . .
107. Resveratrol and N-acetylcysteine block the cancer-initiating step in MCF-10F cells.
108. Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture.
109. Resveratrol, a phytoestrogen found in red wine, down-regulates protein S expression in HepG2 cells.
110. Colorectal cancer: chemopreventive role of curcumin and resveratrol.
111. Activation of the erythrocyte plasma membrane redox system by resveratrol: a possible mechanism for antioxidant properties.
112. Role of phenolic compounds in nitric oxide synthase activity in colon and breast adenocarcinoma.
113. Enhancing Melanoma Treatment with Resveratrol.
114. Neuroprotective properties of resveratrol in different neurodegenerative disorders.
115. Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor α expression . . .
116. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients.
117. The potential use of protein kinase D inhibitors for prevention/treatment of epidermal tumors.
118. Measurement of cyclooxygenase inhibition using liquid chromatography-tandem mass spectrometry.
119. Dihydro-resveratrol--a potent dietary polyphenol.
120. Updates of mTOR inhibitors.
121. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of . . . (fascinating data)
122. Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human . . .
123. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
124. Synthesis of heterocycle-based analogs of resveratrol and their antitumor and vasorelaxing properties.
125. Resveratrol-induced p53-independent apoptosis of human nasopharyngeal carcinoma cells is correlated with the downregulation of ΔNp63.
126. Resveratrol-induced cytotoxicity in human Burkitt's lymphoma cells is coupled to the unfolded protein response.
127. Resveratrol targets transforming growth factor-β2 signaling to block UV-induced tumor progression.
128. Resveratrol induces apoptosis of human nasopharyngeal carcinoma cells via activation of multiple apoptotic pathways.
129. Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety.
130. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study.
131. Estrogen receptor expression is required for low-dose resveratrol-mediated repression of aryl hydrocarbon receptor activity.
132. Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.
133. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer.
134. Cancer prevention with natural compounds.
135. Natural compounds in the human diet and their ability to bind mutagens prevents DNA-mutagen intercalation.
136. Identification of components of grape powder with anti-apoptotic effects.
137. Resveratrol modulates angiogenesis through the GSK3β/β-catenin/TCF-dependent pathway in human endothelial cells.
138. Resveratrol and derivatives for the prevention and treatment of cancer.
139. Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways . . .
140. [Resveratrol inhibits EGF-induced invasion of human lung adenocarcinoma A549 cells].
141. 5-[(E)-2-(4-[18F]Fluorophenyl)ethenyl]-1,3-benzenediol .
142. [Chemopreventive and chemotherapeutic effect of trans-resveratrol and its analogues in cancer].
143. Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFβ signaling pathway in SW480 cells.
144. Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells.
145. In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer.
146. Resveratrol regulates p66Shc activation in HaCaT cells.
147. Resveratrol: Biological and pharmaceutical properties as anticancer molecule.
148. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD.
149. Anti-tumor effects of bakuchiol, an analogue of resveratrol, on human lung adenocarcinoma A549 cell line.
150. 2,3',4,4',5'-Pentamethoxy-trans-stilbene, a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in mice.
151. AMPK- and p62/SQSTM1-dependent autophagy mediate Resveratrol-induced cell death in chronic myelogenous leukemia.
152. Growth-stimulatory effect of resveratrol in human cancer cells. (a cautionary abstract worth reading)
153. Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma.
154. Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer.
155.
156.
157.
158.
end on #182 of 1336 resveratrol cancer on 09/25/11
end on #262 of 1341 resveratrol cancer on 10/02/11
- Crosstalk between Chemokine Receptor CXCR4 and Cannabinoid Receptor CB(2) in Modulating Breast Cancer Growth and Invasion.
- Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy.
- Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis.
- Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.
- Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.
- Cannabinoids in the treatment of cancer.
- JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells.
- Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells.
- Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.
- Cannabinoids and cancer.
- Control of the cell survival/death decision by cannabinoids.
- Cannabinoids for Treatment of Chronic Non-Cancer Pain; a Systematic Review of Randomized Trials.
- Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa.
- Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy.
- Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.
- Cannabinoids in the treatment of symptoms in cancer and AIDS, 2nd edition #93.
- The endocannabinoid system and cancer: therapeutic implication.
- Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells.
- Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action.
- A combined preclinical therapy of cannabinoids and temozolomide against glioma.
- Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model.
- Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
- Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis.
- Cannabinoids attenuate cancer pain and proliferation in a mouse model.
- Cannabis-derived substances in cancer therapy--an emerging anti-inflammatory role for the cannabinoids.
- Cannabinoid CB₁ receptor is downregulated in clear cell renal cell carcinoma.
- Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells.
- Cannabinoids inhibit cellular respiration of human oral cancer cells.
- The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells.
- A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.
- Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.
- Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1.
- The cannabinoid R+ methanandamide induces IL-6 secretion by prostate cancer PC3 cells.
- Antitumorigenic effects of cannabinoids beyond apoptosis.
- Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.
- Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.
- A population-based case-control study of marijuana use and head and neck squamous cell carcinoma.
- Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism.
- Efficacy of Crude Marijuana and Synthetic Delta-9-Tetrahydrocannabinol as Treatment for Chemotherapy-Induced Nausea and Vomiting . . .
- Cannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies?
- Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications.
- Cannabinoids in intestinal inflammation and cancer.
- Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells.
- Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.
- Do cannabinoids have a role in cancer pain management?
- Role of cannabinoid receptors in bone disorders: alternatives for treatment.
- [Cannabinoids in medicine].
- Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells.
- Endocannabinoids in the retina: from marijuana to neuroprotection.
- Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil.
- Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis.
- Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal . . .
- The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms.
- Antineoplastic and apoptotic effects of cannabinoids. N-acylethanolamines: protectors or killers?
- A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells.
- Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression.
- Cannabinoids in health and disease.
- Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma.
- Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1.
- Cannabinoids as potential new therapy for the treatment of gliomas.
- Cannabinoids and gliomas.
- Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue.
- Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon.
- The cannabinoid CB(2) receptor: a good friend in the gut.
- Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.
- Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity?
- Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo.
- The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis . . .
- Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
- Endocannabinoid system in cancer cachexia.
- Medical marijuana and the developing role of the pharmacist.
- A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study.
- The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists.
- Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
- Marijuana as therapy for people living with HIV/AIDS: social and health aspects.
- Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
- Cancer cachexia and immunomodulation.
- Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review).
- Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.
- HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor.
- Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis.
- Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy.
- Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma.
- Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 . . .
- Cannabinoid receptors as novel targets for the treatment of melanoma.
- Combined cannabinoid therapy via an oromucosal spray.
- The endocannabinoid system as an emerging target of pharmacotherapy.
- Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212-2 is associated with ceramide accumulation . . .
- Cannabinoids in cancer pain management.
- Formation of B and T cell subsets require the cannabinoid receptor CB2.
- Cannabinoids, immune system and cytokine network.
- The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells.
- Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria.
- Cannabinoid receptors in human astroglial tumors.
- Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes.
- Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.
- Therapeutic potential of cannabinoid receptor ligands: current status.
- A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.
- Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression.
101. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells.
102. Effects on cell viability.
103. Cannabinoids and the digestive tract.
104. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells.
105. Cannabinoids in medicine: A review of their therapeutic potential.
106. [Cannabis and cancer].
107. New insights into endocannabinoid degradation and its therapeutic potential.
108. Cannabinoids and cancer: pros and cons of an antitumour strategy.
109. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism.
110. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells.
111. Anandamide inhibits adhesion and migration of breast cancer cells.
112. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma.
113. Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma.
114. R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells.
115. Cannabis and tobacco smoke are not equally carcinogenic.
116. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.
117. p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells.
118. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2.
119. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.
120. Cannabinoids and cancer: potential for colorectal cancer therapy.
121. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol . . .
122. [Palliative pain therapy, cannabinoids].
123. Cannabinoid receptor as a novel target for the treatment of prostate cancer.
124. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism.
125. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion.
126. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain.
127. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas.
128. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans.
129. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation.
130. Hypothesis: cannabinoid therapy for the treatment of gliomas?
131. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids.
132. [Cannabinoids and the immune system. Of men, mice and cells].
133. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1.
134. Cannabinoid receptor systems: therapeutic targets for tumour intervention.
135. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines.
136. Cannabinoids: potential anticancer agents.
137. The cannabinoid system and immune modulation.
138. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals . . .
139. Possible endocannabinoid control of colorectal cancer growth.
140. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor . . .
141. [The endocannabinoid system as a target for the development of new drugs for cancer therapy].
142. Pharmacokinetics and pharmacodynamics of cannabinoids.
143. Established and potential therapeutic applications of cannabinoids in oncology.
144. Inhibition of tumor angiogenesis by cannabinoids.
145. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.
146. Cannabinoids and cell fate.
147. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.
148. Endocannabinoids in the immune system and cancer.
149. Oxidative metabolism of endocannabinoids.
150. [Potential therapeutic usefulness of cannabis and cannabinoids].
(end on 207 of 809 cannabinoid cancer on 10/05/11)
(end on 249 of 809 cannabinoid cancer on 10/05/11)
(end on 356 of 809 cannabinoid cancer on 10/06/11)
(end on 410 of 809 cannabinoid cancer on 10/07/11)
(end on 532 of 809 cannabinoid cancer on 10/08/11)
- Cannabinoids induce cancer cell proliferation via tumor necrosis factor . . . (a study suggesting Marijuana may cause cancer)
- Marijuana smoking and head and neck cancer. (a study suggesting Marijuana may cause cancer)
Dr. Burzynski Antineoplaston Therapy:
- Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.
- Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1.
- Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report.
- Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.
- The present state of antineoplaston research (1).
- Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.
- Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma.
- Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients.
- Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy.
- Phase I clinical studies of antineoplaston A5 injections.
Raw Juicing & Cancer:
- Inhibition of azoxymethane-induced colon cancer by orange juice.
- Effects of Brussels sprout juice on the cell cycle and adhesion of human colorectal carcinoma cells (HT29) in vitro.
- Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices.
- Mechanisms of action and antiproliferative properties of Brassica oleracea juice in human breast cancer cell lines.
- [Study on the inhibitory effects of juice of tomato on the growth of human prostate carcinoma PC-3 cells].
- Inhibition of cancer cell proliferation and suppression of TNF-induced activation of NFkappaB by edible berry juice.
- Prevention of tumour production in rats fed aminopyrine plus nitrite by sea buckthorn juice.
- Apple juice intervention modulates expression of ARE-dependent genes in rat colon and liver.
- Inhibitory effect of tomato juice on rat urinary bladder carcinogenesis after N-butyl-N-(4-hydroxybutyl) nitrosamine initiation.
- Effect of cranberry juice concentrate on chemically-induced urinary bladder cancers.
- The Tg.AC Transgenic Mouse as a Screening Tool for Anticarcinogens: Broccoli Juice Protected Against 12-O-Tetradecanoylphorbol-13-Acetate.
- Cancer chemoprevention by pomegranate: laboratory and clinical evidence.
- Pomegranate and breast cancer: possible mechanisms of prevention.
- Pomegranate fruit extract impairs invasion and motility in human breast cancer.
- Inhibitory effects of green tea and grape juice on the phenol sulfotransferase activity of mouse intestines and human colon carcinoma
- Cranberry juice constituents impair lymphoma growth and augment the generation of antilymphoma antibodies in syngeneic mice.
- Pomegranate juice inhibits sulfoconjugation in Caco-2 human colon carcinoma cells.
- Cancer chemopreventive potential of apples, apple juice, and apple components.
- Cloudy apple juice is more effective than apple polyphenols and an apple juice derived cloud fraction in a rat model of colon carcinogenesis.
- Antioxidant properties of apple juice and its protection against Cr(VI)-induced cellular injury.
- Suppression of 7,12-dimethylbenz[a]anthracene-induced chromosome aberrations in rat bone marrow cells by vegetable juices.
- Stimulation of tumor necrosis factor and interleukin-1 productivity by the oral administration of cabbage juice to rats.
- Mice drinking goji berry juice (Lycium barbarum) are protected from UV radiation-induced skin damage via antioxidant pathways.
- Effect of concord grape juice on chemotherapy-induced nausea and vomiting: results of a pilot study.
Resveratrol:
- Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive . . .
- 5-fluorouracil increases the chemopreventive potentials of resveratrol through DNA damage and MAPK signaling pathway in human colorectal. . .
- Resveratrol Suppresses Constitutive Activation of AKT via Generation of ROS and Induces Apoptosis in Diffuse Large B Cell Lymphoma Cell Lines.
- Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors.
- Formation of diethylstilbestrol-DNA adducts in human breast epithelial cells and inhibition by resveratrol.
- Resveratrol alters microRNA expression profiles in A549 human non-small cell lung cancer cells.
- Resveratrol and Black Tea Polyphenol Combination Synergistically Suppress Mouse Skin Tumors Growth by Inhibition of Activated MAPKs
- Chemical modifications of resveratrol for improved protein kinase C alpha activity.
- Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy.
- Mechanisms regulating enhanced HLA class II-mediated CD4+ T cell recognition of human B-cell lymphoma by resveratrol.
- Application of liposome encapsulation technique to improve anti-carcinoma effect of resveratrol.
- Resveratrol interferes with N-nitrosodiethylamine-induced hepatocellular carcinoma at early and advanced stages in male Wistar rats.
- Resveratrol suppresses human colon cancer cell proliferation and induces apoptosis via targeting the pentose phosphate and the talin-FAK . . .
- Resveratrol, MicroRNAs, Inflammation, and Cancer.
- Comparative effects of retinoic acid, vitamin D and resveratrol alone and in combination with adenosine analogues on methylation and . . .
- Resveratrol ameliorates TNFα-mediated suppression of erythropoiesis in human CD34(+) cells via modulation of NF-κB signalling.
- Resveratrol Oligomers Isolated from Carex Species Inhibit Growth of Human Colon Tumorigenic Cells Mediated by Cell Cycle Arrest.
- Role of 5-lipoxygenase in resveratrol mediated suppression of 7,12-dimethylbenz(α)anthracene-induced mammary carcinogenesis in rats.
- Challenges of Translating Basic Research Into Therapeutics: Resveratrol as an Example.
- Resveratrol induces apoptosis in pancreatic cancer cells.
- Antiproliferation and redifferentiation in thyroid cancer cell lines by polyphenol phytochemicals.
- Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor {alpha} gene expression via . . .
- Endocrine-active chemicals in mammary cancer causation and prevention.
- Resveratrol and prostate cancer: promising role for microRNAs.
- Resveratrol Induces p53-independent, X-linked Inhibitor of Apoptosis Protein (XIAP)-mediated Bax Protein Oligomerization on Mitochondria . . .
- Resveratrol Selectively Induces DNA Damage, Independent of Smad4 Expression, in Its Efficacy against Human Head and Neck Squamous Cell . . .
- Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells.
- Resveratrol inhibits genistein-induced multi-drug resistance protein 2 (MRP2) expression in HepG2 cells.
- Inhibitory effect of resveratrol on the expression of the VEGF gene and proliferation in renal cancer cells.
- Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases--Safety . . .
- Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer. (WOW)
- Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo.
- Resveratrol potentiates grape seed extract induced human colon cancer cell apoptosis.
- Multiple beneficial effects of resveratrol and their chemical-biochemical basis.
- Cellular and molecular effects of sirtuins in health and disease.
- Platinum-based compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention.
- Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18.
- Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents.
- The dietary compounds resveratrol and genistein induce activating transcription factor 3 while suppressing inhibitor of DNA binding/differentiation-1.
- The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine . . .
- Pro-apoptotic versus anti-apoptotic properties of dietary resveratrol on tumoral and normal cardiac cells.
- Resveratrol and its analogues: promising antitumor agents.
- Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis.
- Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells.
- Resveratrol induces cellular senescence with attenuated mono-ubiquitination of histone H2B in glioma cells.
- Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: Phenolic acids, monophenol, polyphenol . . .
- Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment.
- Resveratrol induces apoptosis in breast cancer cells by E2F1-mediated up-regulation of ASPP1.
- Suppression of growth and invasive behavior of human prostate cancer cells by ProstaCaid™: mechanism of activity.
- Resveratrol enhances 5-hydroxytryptamine type 3A receptor-mediated ion currents: the role of arginine 222 residue in pre-transmembrane domain I.
- Endocytosis of resveratrol via lipid rafts and activation of downstream signaling pathways in cancer cells.
- Resveratrol in combination with other dietary polyphenols concomitantly enhances antiproliferation and UGT1A1 induction in Caco-2 cells.
- Alteration of Hepatic Proinflammatory Cytokines is Involved in the Resveratrol-Mediated Chemoprevention of Chemically-Induced . . .
- The novel resveratrol analog HS-1793-induced polyploid LNCaP prostate cancer cells are vulnerable to downregulation of Bcl-xL.
- Resveratrol protects leukemic cells against cytotoxicity induced by proteasome inhibitors via induction of FOXO1 and p27Kip1.
- Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-kappa B-mediated mechanism.
- Resveratrol metabolites do not elicit early pro-apoptotic mechanisms in neuroblastoma cells.
- Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer.
- Resveratrol reduces the invasive growth and promotes the acquisition of a long-lasting differentiated phenotype in human glioblastoma cells.
- Finding more active antioxidants and cancer chemoprevention agents by elongating the conjugated links of resveratrol.
- Quantum-chemical study of interactions of trans-resveratrol with guanine-thymine dinucleotide and DNA-nucleobases.
- Pathobiology and prevention of cancer chemotherapy-induced bone growth arrest, bone loss, and osteonecrosis.
- The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model.
- SOCS-3 antagonizes pro-apoptotic effects of TRAIL and resveratrol in prostate cancer cells.
- Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency . . .
- Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds.
- Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer.
- Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe.
- Fluorinated N,N-dialkylaminostilbenes for Wnt pathway inhibition and colon cancer repression.
- Chemosensitization of tumors by resveratrol.
- Resveratrol in cancer management: where are we and where we go from here?
- Chemopreventive effects of resveratrol and resveratrol derivatives.
- Resveratrol and apoptosis.
- Chemoprevention in experimental animals.
- Resveratrol and cellular mechanisms of cancer prevention.
- Metabolomic analysis of resveratrol-induced effects in the human breast cancer cell lines MCF-7 and MDA-MB-231.
- Resveratrol with antioxidant activity inhibits matrix metalloproteinase via modulation of SIRT1 in human fibrosarcoma cells.
- Regulation of p53 and cell proliferation by resveratrol and its derivatives in breast cancer cells: An in silico and biochemical approach . . .
- Resveratrol interacts with estrogen receptor-β to inhibit cell replicative growth and enhance stress resistance by upregulating mitochondrial . . .
- The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges.
- Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor.
- Resveratrol-induced apoptosis is mediated by early growth response-1, Krüppel-like factor 4, and activating transcription factor 3.
- Role of Na(+)/H (+) exchanger in resveratrol-induced growth inhibition of human breast cancer cells.
- Dose-dependency of resveratrol in providing health benefits. (IMPORTANT to read)
- Resveratrol down-regulates interferon-γ-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation.
- Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase.
- Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation.
- Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.
- Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells.
- Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by . . .
- Inhibition of NF-κB signaling commits resveratrol-treated medulloblastoma cells to apoptosis without neuronal differentiation.
- Resveratrol attenuates doxorubicin-induced cellular damage by modulating nitric oxide and apoptosis.
- SIRT1 deficiency attenuates MPP+-induced apoptosis in dopaminergic cells.
- The grapevine-shoot extract Vineatrol30 inhibits the chemically induced malignant transformation of BALB/c-3T3 cells.
- Dose-dependent antioxidant function of resveratrol demonstrated via modulation of reactive oxygen species in normal human skin fibroblasts in vitro.
- Anti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice.
- Arachidin-1, a Peanut Stilbenoid, Induces Programmed Cell Death in Human Leukemia HL-60 Cells.
- Control of prostate cell growth, DNA damage and repair and gene expression by resveratrol analogues, in vitro.
- Antiproliferative effect of resveratrol in pancreatic cancer cells.
101. Resveratrol inhibits proliferation and promotes apoptosis of neuroblastoma cells: role of sirtuin 1.
102. Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by inhibiting leukotriene A₄hydrolase.
103. Resveratrol enhances anti-proliferative effect of VACM-1/cul5 in T47D cancer cells.
104. Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular carcinoma Huh-7 cells.
105. Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies.
106. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin . . .
107. Resveratrol and N-acetylcysteine block the cancer-initiating step in MCF-10F cells.
108. Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture.
109. Resveratrol, a phytoestrogen found in red wine, down-regulates protein S expression in HepG2 cells.
110. Colorectal cancer: chemopreventive role of curcumin and resveratrol.
111. Activation of the erythrocyte plasma membrane redox system by resveratrol: a possible mechanism for antioxidant properties.
112. Role of phenolic compounds in nitric oxide synthase activity in colon and breast adenocarcinoma.
113. Enhancing Melanoma Treatment with Resveratrol.
114. Neuroprotective properties of resveratrol in different neurodegenerative disorders.
115. Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor α expression . . .
116. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients.
117. The potential use of protein kinase D inhibitors for prevention/treatment of epidermal tumors.
118. Measurement of cyclooxygenase inhibition using liquid chromatography-tandem mass spectrometry.
119. Dihydro-resveratrol--a potent dietary polyphenol.
120. Updates of mTOR inhibitors.
121. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of . . . (fascinating data)
122. Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human . . .
123. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
124. Synthesis of heterocycle-based analogs of resveratrol and their antitumor and vasorelaxing properties.
125. Resveratrol-induced p53-independent apoptosis of human nasopharyngeal carcinoma cells is correlated with the downregulation of ΔNp63.
126. Resveratrol-induced cytotoxicity in human Burkitt's lymphoma cells is coupled to the unfolded protein response.
127. Resveratrol targets transforming growth factor-β2 signaling to block UV-induced tumor progression.
128. Resveratrol induces apoptosis of human nasopharyngeal carcinoma cells via activation of multiple apoptotic pathways.
129. Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety.
130. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study.
131. Estrogen receptor expression is required for low-dose resveratrol-mediated repression of aryl hydrocarbon receptor activity.
132. Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.
133. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer.
134. Cancer prevention with natural compounds.
135. Natural compounds in the human diet and their ability to bind mutagens prevents DNA-mutagen intercalation.
136. Identification of components of grape powder with anti-apoptotic effects.
137. Resveratrol modulates angiogenesis through the GSK3β/β-catenin/TCF-dependent pathway in human endothelial cells.
138. Resveratrol and derivatives for the prevention and treatment of cancer.
139. Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways . . .
140. [Resveratrol inhibits EGF-induced invasion of human lung adenocarcinoma A549 cells].
141. 5-[(E)-2-(4-[18F]Fluorophenyl)ethenyl]-1,3-benzenediol .
142. [Chemopreventive and chemotherapeutic effect of trans-resveratrol and its analogues in cancer].
143. Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFβ signaling pathway in SW480 cells.
144. Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells.
145. In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer.
146. Resveratrol regulates p66Shc activation in HaCaT cells.
147. Resveratrol: Biological and pharmaceutical properties as anticancer molecule.
148. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD.
149. Anti-tumor effects of bakuchiol, an analogue of resveratrol, on human lung adenocarcinoma A549 cell line.
150. 2,3',4,4',5'-Pentamethoxy-trans-stilbene, a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in mice.
151. AMPK- and p62/SQSTM1-dependent autophagy mediate Resveratrol-induced cell death in chronic myelogenous leukemia.
152. Growth-stimulatory effect of resveratrol in human cancer cells. (a cautionary abstract worth reading)
153. Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma.
154. Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer.
155.
156.
157.
158.
end on #182 of 1336 resveratrol cancer on 09/25/11
end on #262 of 1341 resveratrol cancer on 10/02/11
Are these chemicals safe?
Trastuzumab (containing) Chemotherapy: Trade name Herceptin is a monoclonal antibody that interferes with the HER2/neu receptor. Trastuzumab is also controversial because of its cost, as much as $100,000 per year,[3]
Concern
Carboplatin (containing) Chemotherapy: Trade names Paraplatin and Paraplatin-AQ is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers). It was introduced in the late 1980s and has since gained popularity in clinical treatment due to its vastly reduced side-effects compared to its parent compound cisplatin. Cisplatin and carboplatin, as well as oxaliplatin, interact with DNA, akin to the mechanism of alkylating agents.
Concern
Concern
- [Appearance of skin and nail toxicity in patients with breast cancer who underwent trastuzumab-containing chemotherapy].
- Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.
- Dermatological side effects of current and upcoming targeted therapies in oncology.
- Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity . . .
- [Cardiac safety of trastuzumab in adjuvant: a review across 53 observations].
- Cardiotoxicity associated with targeting kinase pathways in cancer.
- Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic . . .
- Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
- Cardiovascular effects of systemic cancer treatment.
- Observation of de novo bladder dysfunction under treatment with Her2-neu antibodies.
- Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?
- Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
- Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis.
- Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
- Insights into cardiovascular side-effects of modern anticancer therapeutics.
- Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway.
- [Trastuzumab-associated cardiac dysfunction].
- Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy.
- [Organizing pneumonia associated with the use of trastuzumab].
- A throbbing pain in the head: trastuzumab-induced migraine.
- Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study.
- Fatal pneumonitis after treatment with docetaxel and trastuzumab.
- Trastuzumab (Herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute . . .
- Trastuzumab: unusual responses and toxicities.
- [Cardiotoxicity of drugs used in oncology].
Carboplatin (containing) Chemotherapy: Trade names Paraplatin and Paraplatin-AQ is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers). It was introduced in the late 1980s and has since gained popularity in clinical treatment due to its vastly reduced side-effects compared to its parent compound cisplatin. Cisplatin and carboplatin, as well as oxaliplatin, interact with DNA, akin to the mechanism of alkylating agents.
Concern
- Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.
- Carboplatin side effect: Toxic skin eruption
- Pravastatin attenuates carboplatin-induced nephrotoxicity in rodents via peroxisome proliferator-activated receptor alpha-regulated heme . . .
- N-acetylcysteine and N-nitroarginine methyl ester attenuate Carboplatin-induced ototoxicity in dissociated spiral ganglion neuron cultures.
- Hearing impairment after platinum-based chemotherapy in childhood.
- Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
- Carboplatin-Induced Hematuria in a Patient of Breast Carcinoma. A Case Report.
- Carboplatin and docetaxel-induced acute pancreatitis: brief report.
- Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma.
- [Acute myocardial infarction induced by lung cancer chemotherapy after radiation of left lung].
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Words From Doctors
"More people live off cancer than die from it."
Dr. Deepak Chopra, M.D.
"What she (Dr. Johanna Budwig) has demonstrated to my initial disbelief but lately, to my complete satisfaction in my practice is: CANCER IS EASILY CURABLE, the treatment is dietary/lifestyle, the response is immediate; the cancer cell is weak and vulnerable; the precise biochemical breakdown point was identified by her in 1951 and is specifically correctable, in vitro (test-tube) as well as in vivo (real)... "
Dr. Dan C. Roehm M.D. FACP (Oncologists and former cardiologist) in 1990
"The FDA, NCI and ACS, and the large treatment centres work to eliminate choice of cancer therapies, particulary better ones. They openly attack breakthroughs made by "mavericks", which they define as anyone outside their ranks. Folks, any serious study of how these entities work together to destroy hopeful approaches to cancer reveals a trail of corruption, conspiracy, dishonesty, and inhumanity that warrants desigantion of evil……..We continue to use them not because they work, but because those who perform them have so vigorously eliminated any other choice.
First, I would not even check in with a conventional oncologist, particulary not one from a prominent cancer institution. Their expertise is in implementing the erroneous paradigm that cancer must be purged from the body with toxic methods. This is, in my opinion, no more valuable than maps from the Flat Earth Society. When there is a paradigm shift---and we definitely are in the middle of one with cancer treatment---those sitting on the lofty perches of authority are the last to make the change, because they are guarding the paradigm about to be replaced. I don’t buy maps of a flat earth, and I wouldn’t go to the NCI or Memorial Sloan-Kettering Centre for cancer treatment.
I’d turn my back on 50 years of institutionalised expertise, because it follows the wrong paradigm. Everything that is done in medicine today or in any other discipline fits some paradigm. The paradigm I use for cancer is that it is a systemic problem in which the normal control mechanisms of your body are altered. Your immune system likely bears the largest burden for this control; thus, all techniques that enhance it are promising. Those that damage it are not."
Dr. Julian Whitaker, M.D.
"As a chemist trained to interpret data, it is incomprehensible to me that physicians can ignore the clear evidence that chemotherapy does much, much more harm than good."
Alan Nixon, Ph.D., Past President, American Chemical Society
"Two to 4% of cancers respond to chemotherapy……The bottom line is for a few kinds of cancer chemo is a life extending procedure---Hodgkin's disease, Acute Lymphocytic Leukemia, Testicular cancer, and Choriocarcinoma."
Ralph Moss, Ph.D. 1995 Author of Questioning Chemotherapy
"We have a multi-billion dollar industry that is killing people, right and left, just for financial gain. Their idea of research is to see whether two doses of this poison is better than three doses of that poison."
"Chemotherapy is an incredibly lucrative business for doctors, hospitals, and pharmaceutical companies…..The medical establishment wants everyone to follow the same exact protocol. They don’t want to see the chemotherapy industry go under, and that’s the number one obstacle to any progress in oncology."
Dr. Glen Warner, M.D. Oncologist
"The thing that bugs me is that the people think the FDA is protecting them. It isn’t. What the FDA is doing and what the public thinks it’s doing are as different as night and day."
Dr. Ley former Commissioner of the FDA
"What made Dr Burzynski a threat to the cancer industry from the beginning was the prospect that antineoplaston therapy represented a successful alternative to toxic and dangerous chemotherapy drugs, upon which most of the cancer industry’s profits depend. Did the NCI pick up the tab for completing his research? Did the ACS help with favourable publicity? Of course not. The minute NCI saw evidence of antineoplastons working they distorted the data by withdrawing the 2 successful patients and thus the evidence. NCI’s conduct towards him is a striking example of how an agency presumed to be objective can set up a study that will either prove or disprove anything it wants. In this case, there is clear evidence that NCI wanted to prove antineoplastons didn’t work."
John Diamond, M.D. & Lee Cowden, M.D.
"Most cancer patients in this country die of chemotherapy. Chemotherapy does not eliminate breast, colon, or lung cancers. This fact has been documented for over a decade, yet doctors still use chemotherapy for these tumors."
Allen Levin, MD UCSF The Healing of Cancer
"More people live off cancer than die from it."
Dr. Deepak Chopra, M.D.
"What she (Dr. Johanna Budwig) has demonstrated to my initial disbelief but lately, to my complete satisfaction in my practice is: CANCER IS EASILY CURABLE, the treatment is dietary/lifestyle, the response is immediate; the cancer cell is weak and vulnerable; the precise biochemical breakdown point was identified by her in 1951 and is specifically correctable, in vitro (test-tube) as well as in vivo (real)... "
Dr. Dan C. Roehm M.D. FACP (Oncologists and former cardiologist) in 1990
"The FDA, NCI and ACS, and the large treatment centres work to eliminate choice of cancer therapies, particulary better ones. They openly attack breakthroughs made by "mavericks", which they define as anyone outside their ranks. Folks, any serious study of how these entities work together to destroy hopeful approaches to cancer reveals a trail of corruption, conspiracy, dishonesty, and inhumanity that warrants desigantion of evil……..We continue to use them not because they work, but because those who perform them have so vigorously eliminated any other choice.
First, I would not even check in with a conventional oncologist, particulary not one from a prominent cancer institution. Their expertise is in implementing the erroneous paradigm that cancer must be purged from the body with toxic methods. This is, in my opinion, no more valuable than maps from the Flat Earth Society. When there is a paradigm shift---and we definitely are in the middle of one with cancer treatment---those sitting on the lofty perches of authority are the last to make the change, because they are guarding the paradigm about to be replaced. I don’t buy maps of a flat earth, and I wouldn’t go to the NCI or Memorial Sloan-Kettering Centre for cancer treatment.
I’d turn my back on 50 years of institutionalised expertise, because it follows the wrong paradigm. Everything that is done in medicine today or in any other discipline fits some paradigm. The paradigm I use for cancer is that it is a systemic problem in which the normal control mechanisms of your body are altered. Your immune system likely bears the largest burden for this control; thus, all techniques that enhance it are promising. Those that damage it are not."
Dr. Julian Whitaker, M.D.
"As a chemist trained to interpret data, it is incomprehensible to me that physicians can ignore the clear evidence that chemotherapy does much, much more harm than good."
Alan Nixon, Ph.D., Past President, American Chemical Society
"Two to 4% of cancers respond to chemotherapy……The bottom line is for a few kinds of cancer chemo is a life extending procedure---Hodgkin's disease, Acute Lymphocytic Leukemia, Testicular cancer, and Choriocarcinoma."
Ralph Moss, Ph.D. 1995 Author of Questioning Chemotherapy
"We have a multi-billion dollar industry that is killing people, right and left, just for financial gain. Their idea of research is to see whether two doses of this poison is better than three doses of that poison."
"Chemotherapy is an incredibly lucrative business for doctors, hospitals, and pharmaceutical companies…..The medical establishment wants everyone to follow the same exact protocol. They don’t want to see the chemotherapy industry go under, and that’s the number one obstacle to any progress in oncology."
Dr. Glen Warner, M.D. Oncologist
"The thing that bugs me is that the people think the FDA is protecting them. It isn’t. What the FDA is doing and what the public thinks it’s doing are as different as night and day."
Dr. Ley former Commissioner of the FDA
"What made Dr Burzynski a threat to the cancer industry from the beginning was the prospect that antineoplaston therapy represented a successful alternative to toxic and dangerous chemotherapy drugs, upon which most of the cancer industry’s profits depend. Did the NCI pick up the tab for completing his research? Did the ACS help with favourable publicity? Of course not. The minute NCI saw evidence of antineoplastons working they distorted the data by withdrawing the 2 successful patients and thus the evidence. NCI’s conduct towards him is a striking example of how an agency presumed to be objective can set up a study that will either prove or disprove anything it wants. In this case, there is clear evidence that NCI wanted to prove antineoplastons didn’t work."
John Diamond, M.D. & Lee Cowden, M.D.
"Most cancer patients in this country die of chemotherapy. Chemotherapy does not eliminate breast, colon, or lung cancers. This fact has been documented for over a decade, yet doctors still use chemotherapy for these tumors."
Allen Levin, MD UCSF The Healing of Cancer
______________________________________________________________________
"Science is nothing, but trained and organized common sense."
Thomas H. Huxley
______________________________________________________________________
All info is copyrighted except humor photos © 2009-2018 Body Epiphanies Massage & Nutrition
Professional Member of Associated Bodywork & Massage Professionals | Board Certified by NCBTMB
760 E. Warm Springs Ave. | Suite S | Boise, ID 83712 | (208) 870-9753 Boise Massage Therapist & Nutritionist
"Science is nothing, but trained and organized common sense."
Thomas H. Huxley
______________________________________________________________________
All info is copyrighted except humor photos © 2009-2018 Body Epiphanies Massage & Nutrition
Professional Member of Associated Bodywork & Massage Professionals | Board Certified by NCBTMB
760 E. Warm Springs Ave. | Suite S | Boise, ID 83712 | (208) 870-9753 Boise Massage Therapist & Nutritionist